The data obtained from genomic testing can help to identify inherited disorders and tendencies, help predict disease risk, help identify expected drug response, and characterize genetic mutations, including those that drive cancer progression. ProPhase Precision Medicine, Inc., a wholly owned subsidiary of ProPhase, focuses on genomics testing technologies, a comprehensive method for analyzing entire genomes, including the genes and chromosomes in DNA. We have announced plans for the expansion of the lab to include traditional clinical testing and genomics testing. ProPhase Diagnostics also offers best-in-class rapid antigen and antibody/immunity tests to broaden its COVID-19 testing beyond RT-PCR testing. Critical to COVID-19 testing, ProPhase Diagnostics provides fast turnaround times for results. ProPhase Diagnostics, Inc., a wholly owned subsidiary of ProPhase, offers a broad array of clinical diagnostic and testing services at its CLIA certified laboratories including state-of-the-art polymerase chain reaction (PCR) testing for SARS-CoV-2 (COVID-19). The Company also continues to operate a state-of-the-art contract manufacturing subsidiary and the TK Supplements line of dietary supplements, distributed in food, drug and mass stores throughout the country. The Company continues to provide traditional CLIA molecular laboratory services, including COVID-19 testing. (Nasdaq: PRPH) (“ProPhase”) is a diversified diagnostics, genomics and biotech company that seeks to leverage its CLIA lab services to provide whole genome sequencing and research direct to consumers and build a genomics data base to be used for further research. The conference call will be broadcast live and available for replay at and via the investor relations section of the Company's website at A replay of the conference call will be available two hours from when the call ends.
An operator will register your name, phone and organization. Please ask to be joined into the ProPhase Labs, Inc. Please call the conference telephone number 5-10 minutes prior to the start time.
#Prophase labs stock free
Those without internet access or unable to pre-register may dial in to the conference call by calling: Toll free dial in number: Pre-registration required fields of information include: name, phone, company, email. Please note that registered participants will receive their dial in number upon registration. Participants can register for the conference call by navigating to: To access the call, please use the following information: Date:ġ1:00 a.m.
ProPhase Labs’ CEO and Chairman of the Board of Directors, Ted Karkus, will host the conference call, followed by a question-and-answer period. A press release detailing these results will be issued prior to the call. Eastern time to discuss its results for the second quarter ended June 30,2022. 04, 2022 (GLOBE NEWSWIRE) - ProPhase Labs, Inc. (NASDAQ: PRPH), a growth oriented and diversified diagnostics, genomics and biotech company, will hold a conference call on Thursday, Augat 11:00 a.m.
0 kommentar(er)
